Leaping ahead

A novel antibody-only approach, for selective and deep depletion of pathogenic cells, without dependence on immune effector functions or conjugated payloads

… THE PRECISION AND DRUG-LIKE QUALITIES OF ANTIBODIES

Selective cell depletion

Olethros is an innovative biotech company, which builds on groundbreaking technology platforms to discover and develop multifunctional antibodies for selective and deep depletion of tissue-resident, disease-causing cells. These antibodies are designed to act without the need for conventional, potency-enhancing features such as crosslinking by exogenous factors, complement activation, conjugation with toxic payloads or the recruitment of immune effector cells. Consequently, our antibodies achieve an optimal therapeutic window, independent of effector cells or soluble components within the tissue microenvironment.

… FOUNDED ON SCIENCE, BACKED BY EXPERIENCE

Olethros was founded by antibody pioneers Ton Logtenberg and Paul Parren, who invented and developed a range of antibody platforms and numerous clinical phase and marketed therapeutic antibodies. Hui Liu joined Olethros in August 2025 as CEO, to lead the team to transform the promise of our technology into therapies for patients and value for shareholders.
Paul W.H.I. Parren, PhD
Co-founder and Chief Scientific Officer
Hui Liu, PhD, MBA
Chief Executive Officer
Ton Logtenberg, PhD
Co-founder and member of the Board of Directors